共 24 条
[1]
Dahlof B(2002)for The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol Lancet 359 995-1003
[2]
Devereux RB(2004)β-Blocker based antihypertensive therapy is associated with better control of blood pressure and short-term cardiovascular rish in hypertensive smokers (STEFI Study) High Blood Press Cardiovasc Prev 11 91-8
[3]
Kjeldsen SE(2003)(ESC) guidelines for the management of arterial hypertension J Hypertens 21 1011-53
[4]
Di Somma S(2001)Impact of high-normal BP on the risk of cardiovascular disease N Engl J Med 345 1291-7
[5]
Micheli D(1996)Controlling hypertension: a research success story Arch Intern Med 156 1926-35
[6]
Costa B(2002)Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-13
[7]
Vasan RS(2004)Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial Lancet 363 2022-31
[8]
Larson MG(2004)BP dependent and independent effects of antihypertensive treatment on clinical events in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial Lancet 363 2049-51
[9]
Leip EP(1994)Hypertension as worsening factor for left ventricular contractility and function in patients with unstable angina High Blood Press Cardiovasc Prev 3 18-22
[10]
Dustan HP(undefined)undefined undefined undefined undefined-undefined